(Q38824661)

6 September 2017

1 reference

title

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling (English)

1 reference

6 September 2017

1

1 reference

6 September 2017

6

Brian A Hemmings

1 reference

6 September 2017

Mario Mandalà

2

1 reference

6 September 2017

Daniela Massi

3

1 reference

6 September 2017

Daniela Taverna

4

1 reference

6 September 2017

Huifang Tang

5

1 reference

6 September 2017

Gongda Xue

7

1 reference

6 September 2017

publication date

1 July 2016

1 reference

6 September 2017

published in

Physiological Reviews

1 reference

6 September 2017

volume

96

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

805-829

1 reference

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mammary tumor formation and metastasis evoked by a HER2 splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumour heterogeneity in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Vemurafenib: the first drug approved for BRAF-mutant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The causes and consequences of genetic heterogeneity in cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Progression of RAS-mutant leukemia during RAF inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Treating ALK-positive lung cancer--early successes and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Pertuzumab: new hope for patients with HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Role of HER receptors family in development and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mammalian MAP kinase signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Transforming mutations in protein-tyrosine kinase genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Leukocytes in mammary development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The key roles of ERBB2 in cardiac regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Paradoxical roles of the immune system during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumor heterogeneity and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Regulation of Raf-1 by direct feedback phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Role for Akt3/protein kinase Bgamma in attainment of normal brain size

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Medicine: Eyes on the target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PI3K and cancer: lessons, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

On leukocytes in mammary development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumor-associated neutrophils: new targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

ERK inhibition overcomes acquired resistance to MEK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Receptor tyrosine kinases: mechanisms of activation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Targeting DNA repair pathways for cancer treatment: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The PKB/FOXO switch in aging and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Akt-2 binds to Glut4-containing vesicles and phosphorylates their component proteins in response to insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

mTOR signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Membrane recognition by phospholipid-binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Aberrant development of motor axons and neuromuscular synapses in erbB2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

IRES-mediated functional coupling of transcription and translation amplifies insulin receptor feedback

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Regulation of neuroblastoma differentiation by forkhead transcription factors FOXO1/3/4 through the receptor tyrosine kinase PDGFRA

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Multiple essential functions of neuregulin in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tuberous sclerosis complex: linking cancer to metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PD-L1 expression in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Regulation of Raf-Akt Cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Association of MEK1 with p21ras.GMPPNP is dependent on B-Raf

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

21 January 2018

2014 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumor escape mechanism governed by myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Essential roles of Her2/erbB2 in cardiac development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

B-RAF kinase drives developmental axon growth and promotes axon regeneration in the injured mature CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Human EML4, a novel member of the EMAP family, is essential for microtubule formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Macrophage diversity enhances tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Severe neuropathies in mice with targeted mutations in the ErbB3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

DNA damage and the balance between survival and death in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Lymphocytes in cancer development: polarization towards pro-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Receptor tyrosine kinases: legacy of the first two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Heterogeneity in cancer: cancer stem cells versus clonal evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tyrosine kinase gene rearrangements in epithelial malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Making new contacts: the mTOR network in metabolism and signalling crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Targeting cancer epigenetics: Linking basic biology to clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Human tumor cell heterogeneity and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Regulation of PTEN transcription by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The landscape of kinase fusions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Intratumor heterogeneity: evolution through space and time

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Targeting the ERBB family in cancer: couples therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Cancer driver mutations in protein kinase genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PI3K signalling: the path to discovery and understanding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

A functional landscape of resistance to ALK inhibition in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Craf-1 protein kinase is essential for mouse development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Endothelial apoptosis in Braf-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phosphorylation of basic helix-loop-helix transcription factor Twist in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

PKB/Akt-dependent regulation of cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Protein kinase B alpha/Akt1 regulates placental development and fetal growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Intratumor heterogeneity: seeing the wood for the trees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

MST1 promotes apoptosis through regulating Sirt1-dependent p53 deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Regulation of neuronal cell death by MST1-FOXO1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The RAF family: an expanding network of post-translational controls and protein-protein interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

The Hippo pathway acts via p53 and microRNAs to control proliferation and proapoptotic gene expression during tissue growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Phosphorylation and regulation of Raf by Akt (protein kinase B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Nerve Growth Factor-mediated Activation of the Mitogen-activated Protein (MAP) Kinase Cascade Involves a Signaling Complex Containing B-Raf and HSP90

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

Strain-dependent epithelial defects in mice lacking the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSREV.00024.2015

10.1152/PHYSREV.00024.2015

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference